Generics in Japan
Published: August 2013 · Publisher: MarketLine
Generics in Japan industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017).
- Description
- Companies Mentioned
- Table of Contents
- Ask a Question
Introduction
Generics in Japan industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Japan generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
*The Japanese generics market had total revenues of $4.2bn in 2012, representing a compound annual growth rate (CAGR) of 5.3% between 2008 and 2012.
*Market consumption volume increased with a CAGR of 8.4% between 2008-2012, to reach a total of 24.3% of total pharma volume in 2012.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 4.1% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $5.1bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Japan
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Japan
Leading company profiles reveal details of key generics market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Japan generics market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the Japan economy
Key Questions Answered
What was the size of the Japan generics market by value in 2012?
What will be the size of the Japan generics market in 2017?
What factors are affecting the strength of competition in the Japan generics market?
How has the market performed over the last five years?
What are the main segments that make up Japan's generics market?
Generics in Japan industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Japan generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
*The Japanese generics market had total revenues of $4.2bn in 2012, representing a compound annual growth rate (CAGR) of 5.3% between 2008 and 2012.
*Market consumption volume increased with a CAGR of 8.4% between 2008-2012, to reach a total of 24.3% of total pharma volume in 2012.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 4.1% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $5.1bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Japan
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Japan
Leading company profiles reveal details of key generics market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Japan generics market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the Japan economy
Key Questions Answered
What was the size of the Japan generics market by value in 2012?
What will be the size of the Japan generics market in 2017?
What factors are affecting the strength of competition in the Japan generics market?
How has the market performed over the last five years?
What are the main segments that make up Japan's generics market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Daiichi Sankyo Co., Ltd., Nichi-iko Pharmaceutical, Sawai Pharmaceutical Co., Ltd. and Teva Pharmaceutical Industries Limited
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market volume 9
Market Segmentation 10
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Market volume forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Daiichi Sankyo Co., Ltd. 19
Nichi-iko Pharmaceutical 22
Sawai Pharmaceutical Co., Ltd. 25
Teva Pharmaceutical Industries Limited 28
Macroeconomic Indicators 32
Country Data 32
Appendix 34
Methodology 34
Industry associations 35
Related research 35
LIST OF TABLES
Table 1: Japan generics market value: $ million, 2008–12 8
Table 2: Japan generics market volume: % of total pharma volume, 2008–12 9
Table 3: Japan generics market geography segmentation: $ million, 2012 10
Table 4: Japan generics market value forecast: $ million, 2012–17 11
Table 5: Japan generics market volume forecast: % of total pharma volume, 2012–17 12
Table 6: Daiichi Sankyo Co., Ltd.: key facts 19
Table 7: Daiichi Sankyo Co., Ltd.: key financials ($) 19
Table 8: Daiichi Sankyo Co., Ltd.: key financials (¥) 20
Table 9: Daiichi Sankyo Co., Ltd.: key financial ratios 20
Table 10: Nichi-iko Pharmaceutical: key facts 22
Table 11: Nichi-iko Pharmaceutical: key financials ($) 23
Table 12: Nichi-iko Pharmaceutical: key financials (¥) 23
Table 13: Nichi-iko Pharmaceutical: key financial ratios 23
Table 14: Sawai Pharmaceutical Co., Ltd.: key facts 25
Table 15: Sawai Pharmaceutical Co., Ltd.: key financials ($) 25
Table 16: Sawai Pharmaceutical Co., Ltd.: key financials (¥) 26
Table 17: Sawai Pharmaceutical Co., Ltd.: key financial ratios 26
Table 18: Teva Pharmaceutical Industries Limited: key facts 28
Table 19: Teva Pharmaceutical Industries Limited: key financials ($) 29
Table 20: Teva Pharmaceutical Industries Limited: key financial ratios 30
Table 21: Japan size of population (million), 2008–12 32
Table 22: Japan gdp (constant 2000 prices, $ billion), 2008–12 32
Table 23: Japan gdp (current prices, $ billion), 2008–12 32
Table 24: Japan inflation, 2008–12 33
Table 25: Japan consumer price index (absolute), 2008–12 33
Table 26: Japan exchange rate, 2008–12 33
LIST OF FIGURES
Figure 1: Japan generics market value: $ million, 2008–12 8
Figure 2: Japan generics market volume: % of total pharma volume, 2008–12 9
Figure 3: Japan generics market geography segmentation: % share, by value, 2012 10
Figure 4: Japan generics market value forecast: $ million, 2012–17 11
Figure 5: Japan generics market volume forecast: % of total pharma volume, 2012–17 12
Figure 6: Forces driving competition in the generics market in Japan, 2012 13
Figure 7: Drivers of buyer power in the generics market in Japan, 2012 14
Figure 8: Drivers of supplier power in the generics market in Japan, 2012 15
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Japan, 2012 16
Figure 10: Factors influencing the threat of substitutes in the generics market in Japan, 2012 17
Figure 11: Drivers of degree of rivalry in the generics market in Japan, 2012 18
Figure 12: Daiichi Sankyo Co., Ltd.: revenues & profitability 21
Figure 13: Daiichi Sankyo Co., Ltd.: assets & liabilities 21
Figure 14: Nichi-iko Pharmaceutical: revenues & profitability 24
Figure 15: Nichi-iko Pharmaceutical: assets & liabilities 24
Figure 16: Sawai Pharmaceutical Co., Ltd.: revenues & profitability 26
Figure 17: Sawai Pharmaceutical Co., Ltd.: assets & liabilities 27
Figure 18: Teva Pharmaceutical Industries Limited: revenues & profitability 30
Figure 19: Teva Pharmaceutical Industries Limited: assets & liabilities 31
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market volume 9
Market Segmentation 10
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Market volume forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Daiichi Sankyo Co., Ltd. 19
Nichi-iko Pharmaceutical 22
Sawai Pharmaceutical Co., Ltd. 25
Teva Pharmaceutical Industries Limited 28
Macroeconomic Indicators 32
Country Data 32
Appendix 34
Methodology 34
Industry associations 35
Related research 35
LIST OF TABLES
Table 1: Japan generics market value: $ million, 2008–12 8
Table 2: Japan generics market volume: % of total pharma volume, 2008–12 9
Table 3: Japan generics market geography segmentation: $ million, 2012 10
Table 4: Japan generics market value forecast: $ million, 2012–17 11
Table 5: Japan generics market volume forecast: % of total pharma volume, 2012–17 12
Table 6: Daiichi Sankyo Co., Ltd.: key facts 19
Table 7: Daiichi Sankyo Co., Ltd.: key financials ($) 19
Table 8: Daiichi Sankyo Co., Ltd.: key financials (¥) 20
Table 9: Daiichi Sankyo Co., Ltd.: key financial ratios 20
Table 10: Nichi-iko Pharmaceutical: key facts 22
Table 11: Nichi-iko Pharmaceutical: key financials ($) 23
Table 12: Nichi-iko Pharmaceutical: key financials (¥) 23
Table 13: Nichi-iko Pharmaceutical: key financial ratios 23
Table 14: Sawai Pharmaceutical Co., Ltd.: key facts 25
Table 15: Sawai Pharmaceutical Co., Ltd.: key financials ($) 25
Table 16: Sawai Pharmaceutical Co., Ltd.: key financials (¥) 26
Table 17: Sawai Pharmaceutical Co., Ltd.: key financial ratios 26
Table 18: Teva Pharmaceutical Industries Limited: key facts 28
Table 19: Teva Pharmaceutical Industries Limited: key financials ($) 29
Table 20: Teva Pharmaceutical Industries Limited: key financial ratios 30
Table 21: Japan size of population (million), 2008–12 32
Table 22: Japan gdp (constant 2000 prices, $ billion), 2008–12 32
Table 23: Japan gdp (current prices, $ billion), 2008–12 32
Table 24: Japan inflation, 2008–12 33
Table 25: Japan consumer price index (absolute), 2008–12 33
Table 26: Japan exchange rate, 2008–12 33
LIST OF FIGURES
Figure 1: Japan generics market value: $ million, 2008–12 8
Figure 2: Japan generics market volume: % of total pharma volume, 2008–12 9
Figure 3: Japan generics market geography segmentation: % share, by value, 2012 10
Figure 4: Japan generics market value forecast: $ million, 2012–17 11
Figure 5: Japan generics market volume forecast: % of total pharma volume, 2012–17 12
Figure 6: Forces driving competition in the generics market in Japan, 2012 13
Figure 7: Drivers of buyer power in the generics market in Japan, 2012 14
Figure 8: Drivers of supplier power in the generics market in Japan, 2012 15
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Japan, 2012 16
Figure 10: Factors influencing the threat of substitutes in the generics market in Japan, 2012 17
Figure 11: Drivers of degree of rivalry in the generics market in Japan, 2012 18
Figure 12: Daiichi Sankyo Co., Ltd.: revenues & profitability 21
Figure 13: Daiichi Sankyo Co., Ltd.: assets & liabilities 21
Figure 14: Nichi-iko Pharmaceutical: revenues & profitability 24
Figure 15: Nichi-iko Pharmaceutical: assets & liabilities 24
Figure 16: Sawai Pharmaceutical Co., Ltd.: revenues & profitability 26
Figure 17: Sawai Pharmaceutical Co., Ltd.: assets & liabilities 27
Figure 18: Teva Pharmaceutical Industries Limited: revenues & profitability 30
Figure 19: Teva Pharmaceutical Industries Limited: assets & liabilities 31
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.